0914 GMT - AstraZeneca's investment in Summit Therapeutics gives the U.K. drugmaker skin in the game of an emerging class of cancer drugs, UBS analysts say in a research note. Miami-based Summit is developing a cancer drug called ivonescimab that blocks two proteins known as PD-1 and VEGF. Evidence is emerging that this drug class might be superior to Merck's blockbuster medicine Keytruda and recent data also point to potential for combinations with antibody-drug conjugates, according to UBS. AstraZeneca has an extensive antibody-drug-conjugate portfolio and the Summit deal allows it to generate data across multiple tumor types, the analysts say. "If the PD-1/VEGF class does become the new standard of care in various cancers, it will be important to have such combination data," they add. AstraZeneca shares rise 1.9%.